隨著腫瘤對人類健康的威脅逐漸加大，人類對癌癥的細胞生物學和生物醫學研究有了飛速的發展，癌基因、抑癌基因、細胞凋亡、腫瘤血管形成等使腫瘤研究由細胞生物學水平轉變到分子生物學水平[1]。以膜上或細胞內特異性表達或高表達的分子為作用靶點，包括靶向酪氨酸激酶，血管新生，腫瘤細胞周期相關因子，組蛋白去乙酰酶抑制劑，微環境，腫瘤干細胞，腫瘤代謝異常等因素成為研究靶點特異性抗腫瘤藥物的關鍵[2]。百靈威作為專業試劑供應商，可提供120余種腫瘤研究靶點抑制劑和激活劑產品。
- 多種熱門靶點抑制劑，滿足前沿科研需求
- 作用靶點清晰，易于客戶選擇
- 產品純度高，質量穩定，現貨供應
.png)
圖1:Immunofluorescence and flow cytometric analyses of the translocation of ABCG2 in MCF-7 FLV1000 cells before and after treatment with the PI3K inhibitor LY294002[3].
References
[1] Mbengue A, Bhattacharjee S, Pandharkar T, et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria[J]. Nature, 2015, 520(7549):683-7.
[2] Sapey E, Greenwood H, Walton G, Mann E, Love A, Aaronson N, Insall RH, Stockley RA, Lord JM: Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence[J]. Blood. 2014,123(2):239-248.
[3] To K K W, Tomlinson B. Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists[J]. British Journal of Pharmacology, 2013, 170(5):1137–1151.
■ 腫瘤研究化合物
|
產品編號
|
英文名稱
|
中文名稱
|
CAS
|
作用靶點
|
|
150037
|
5-Azacytidine, 99%
|
5-氮雜胞嘧啶核苷, 99%
|
320-67-2
|
DNA Methyltransferase抑制劑
|
|
268355
|
2-Amino-6-purinethiol, 98%
|
2-氨基-6-嘌呤硫醇, 98%
|
154-42-7
|
DNA Methyltransferase抑制劑
|
|
180939
|
5-Fluorouracil, 99%
|
5-氟尿嘧啶, 99%
|
51-21-8
|
DNA/RNA Synthesis抑制劑
|
|
251696
|
Oxaliplatin, 95%
|
奧沙利鉑, 95%
|
61825-94-3
|
DNA/RNA Synthesis抑制劑
|
|
258050
|
2-Chloro-2'-deoxyadenosine, 99%
|
2-氯-2'-脫氧腺苷, 99%
|
4291-63-8
|
DNA/RNA Synthesis抑制劑
|
|
271269
|
Gemcitabine hydrochloride, 99%
|
鹽酸吉西他濱, 99%
|
122111-03-9
|
DNA/RNA Synthesis抑制劑
|
|
274584
|
Carboplatin, 98%
|
碳鉑, 98%
|
41575-94-4
|
DNA/RNA Synthesis抑制劑
|
|
275688
|
cis-Diamineplatinum(II) dichloride, 99%
|
順式-二氨二氯化鉑, 99%
|
15663-27-1
|
DNA/RNA Synthesis抑制劑
|
|
381488
|
Ara-G hydrate, 98%
|
阿糖鳥苷, 98%
|
38819-10-2
|
DNA/RNA synthesis抑制劑
|
|
341249
|
Erlotinib, 98%
|
埃羅替尼, 98%
|
183321-74-6
|
EGFR抑制劑
|
|
795123
|
Lapatinib ditosylate, 98%
|
二甲苯磺酸拉帕替尼, 98%
|
388082-77-7
|
EGFR抑制劑
|
|
831262
|
Lapatinib, 98%
|
拉帕替尼, 98%
|
231277-92-2
|
EGFR抑制劑
|
|
996037
|
Afatinib, 98%
|
阿法替尼, 98%
|
850140-72-6
|
EGFR抑制劑
|
|
303595
|
Trichostatin A, 98%
|
曲古柳菌素A, 98%
|
58880-19-6
|
HDAC抑制劑
|
|
628151
|
Vorinostat, 99%
|
伏立諾他, 99%
|
149647-78-9
|
HDAC抑制劑
|
|
625238
|
Entinostat, 99%
|
恩替諾特, 99%
|
209783-80-2
|
HDAC抑制劑
|
|
837002
|
Panobinostat, 98%
|
帕比司他, 98%
|
404950-80-7
|
HDAC抑制劑
|
|
1349106
|
Ruxolitinib phosphate salt, 99%
|
魯索利替尼磷酸鹽, 99%
|
1092939-17-7
|
JAK抑制劑
|
|
1430418
|
Tofacitinib citrate, 99%
|
檸檬酸托法替尼, 99%
|
540737-29-9
|
JAK抑制劑
|
|
912849
|
Tofacitinib, 99%
|
托法替尼, 99%
|
477600-75-2
|
JAK抑制劑
|
|
951485
|
Ruxolitinib, 99%
|
魯索替尼, 99%
|
941678-49-5
|
JAK抑制劑
|
|
1272662
|
Cabazitaxel, 99%
|
卡巴他賽, 99%
|
183133-96-2
|
Microtubule Associated抑制劑
|
|
181603
|
Docetaxel, 98%
|
多西他賽, 98%
|
114977-28-5
|
Microtubule Associated抑制劑
|
|
266725
|
Combretastatin A-4, 98%
|
康普瑞汀, 98%
|
117048-59-6
|
Microtubule Associated抑制劑
|
|
369172
|
6-Amino-3-methylpurine, 90%
|
6-氨基-3-甲基嘌呤, 90%
|
5142-23-4
|
PI3K抑制劑
|
|
268623
|
Quercetin, 98%
|
槲皮素, 98%
|
117-39-5
|
PI3K抑制劑
|
|
114089
|
7-Ethyl-10-hydroxycamptothecin, 99%
|
7-乙基-10-羥基喜樹堿, 99%
|
86639-52-3
|
Topoisomerase抑制劑
|
|
116557
|
Daunorubicin hydrochloride, 97%
|
道諾霉素鹽酸鹽, 97%
|
23541-50-6
|
Topoisomerase抑制劑
|
|
194237
|
Epirubicin hydrochloride, 98%
|
表柔比星鹽酸鹽, 98%
|
56390-09-1
|
Topoisomerase抑制劑
|
|
814262
|
Vandetanib, 99%
|
凡德他尼, 99%
|
443913-73-3
|
VEGFR2抑制劑
|
|
1109982
|
Vatalanib dihydrochloride, 99%
|
瓦他拉尼堿二鹽酸鹽, 99%
|
212141-51-0
|
VEGFR2抑制劑
|
|
1239124
|
Ponatinib, 99%
|
帕納替尼, 99%
|
943319-70-8
|
VEGFR2抑制劑
|
|
812864
|
Axitinib, 98%
|
阿西替尼, 98%
|
319460-85-0
|
VEGFR2抑制劑
|
|
1386067
|
A 769662, 98%
|
A 769662, 98%
|
844499-71-4
|
AMPK激活劑
|
■ 相關產品：